Study on glycemic control, weight, body fat and insulin resistance in SGLT2 inhibitor-treated Japanese patients

Study on glycemic control, weight, body fat and insulin resistance in SGLT2 inhibitor-treated Japanese patients - SGLT2 Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016635

Enrollment

Registered

2015-03-01

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Take CANAGLU Tablets 100mg at the oral. 1tablet/day Period of 24 weeks Conducted blood sampling and body fat,abdominalCT ,etc. before and after intervention.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Informed consent obtained in writing before any trial-related activities. Type 2 Diabetes Age <= 70 years old HbA1c between 7.0% and 10.0% BMI >= 23 kg/m2 Creatinine < 1.0mg/dL for male < 0.8mg/dL for female

Exclusion criteria

Exclusion criteria: Extreme low carbohydrate therapy practitioner. Considered as inappropriate by the attending physician. A person who falls under contraindication in the medical package insert.

Design outcomes

Primary

Measure	Time frame
HbA1c ,FPG ,Body weight ,Body mass index ,Body fat	—

Secondary

Measure	Time frame
Visceral fat area ,Waist circumference ,Amount of body fat distribution ,Lean body weight ,HOMA-IR ,HOMA-b ,iHOMA2 ,Blood pressure ,Lipid ,Uric acid ,eGFR ,GIR ,Liver function ,Renal function ,Adiponectin ,TNFa ,IL-6 ,NTpro-BNP	—

Countries

Japan

Contacts

Public ContactTakashi Makuuchi

Medical Corporation H.E.C Science Clinic Clinical Trial Secretariat

hec-soum@asahi-net.email.ne.jp045-831-0031

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026